PMID- 33621130
OWN - NLM
STAT- MEDLINE
DCOM- 20210310
LR  - 20221207
IS  - 1557-7465 (Electronic)
IS  - 1079-9907 (Linking)
VI  - 41
IP  - 2
DP  - 2021 Feb
TI  - Perspectives on Targeting IL-6 as a Potential Therapeutic Strategy for COVID-19.
PG  - 37-43
LID - 10.1089/jir.2020.0135 [doi]
AB  - Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory 
      syndrome coronavirus 2 (SARS-CoV-2) and has been a major threat to global public 
      health. In Indonesia, the cases have rapidly increased, and the case fatality 
      rate remains high. With COVID-19, most of the deaths have been caused by acute 
      respiratory distress syndrome and dysregulation of the immune response. A lung 
      biopsy from a patient with COVID-19 showed inflammatory cellular infiltration 
      with diffuse alveolar damage. Massive pulmonary destruction has also been 
      reported as a result of highly increased levels of proinflammatory cytokines, 
      such as tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), IL-1beta, 
      interferon-gamma (IFN-gamma), induced protein 10 (IP-10), and monocyte chemoattractant 
      protein-1 (MCP-1). IL-6 is an inflammatory cytokine produced by various cell 
      types, including immune cells and nonleukocytes, such as endothelial cells, 
      fibroblasts, epithelial cells, type II pneumocytes, and certain tumor cells. 
      Several studies have shown that IL-6 contributes to the severity and mortality of 
      COVID-19. In this review, we would like to explore the immune response in 
      COVID-19 and the role of IL-6 in the immunopathogenesis of COVID-19.
FAU - Khaedir, Yordan
AU  - Khaedir Y
AD  - Department of Histology, Faculty of Medicine, Universitas Indonesia, Jakarta 
      Pusat, Indonesia.
AD  - Immunology, Master's Program in Biomedical Sciences, Faculty of Medicine, 
      Universitas Indonesia, Jakarta Pusat, Indonesia.
FAU - Kartika, Rona
AU  - Kartika R
AD  - Division of Metabolic, Endocrinology, and Diabetes, Department of Internal 
      Medicine, Faculty of Medicine, Universitas Indonesia, Jakarta Pusat, Indonesia.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - United States
TA  - J Interferon Cytokine Res
JT  - Journal of interferon & cytokine research : the official journal of the 
      International Society for Interferon and Cytokine Research
JID - 9507088
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (IL6 protein, human)
RN  - 0 (Interleukin-6)
RN  - 0 (Janus Kinase Inhibitors)
RN  - 0 (Nitriles)
RN  - 0 (Pyrazoles)
RN  - 0 (Pyrimidines)
RN  - 0 (Receptors, Interleukin-6)
RN  - 82S8X8XX8H (ruxolitinib)
RN  - EC 2.7.10.2 (JAK1 protein, human)
RN  - EC 2.7.10.2 (JAK2 protein, human)
RN  - EC 2.7.10.2 (Janus Kinase 1)
RN  - EC 2.7.10.2 (Janus Kinase 2)
RN  - I031V2H011 (tocilizumab)
RN  - NU90V55F8I (sarilumab)
SB  - IM
MH  - Antibodies, Monoclonal, Humanized/therapeutic use
MH  - COVID-19/*pathology
MH  - Cytokine Release Syndrome/drug therapy/pathology/prevention & control
MH  - Humans
MH  - Indonesia
MH  - Interleukin-6/immunology
MH  - Janus Kinase 1/antagonists & inhibitors
MH  - Janus Kinase 2/antagonists & inhibitors
MH  - Janus Kinase Inhibitors/therapeutic use
MH  - Nitriles
MH  - Pyrazoles/therapeutic use
MH  - Pyrimidines
MH  - Receptors, Interleukin-6/*antagonists & inhibitors
MH  - Respiratory Distress Syndrome/*drug therapy
MH  - SARS-CoV-2/drug effects/*immunology
MH  - Signal Transduction/immunology
MH  - COVID-19 Drug Treatment
OTO - NOTNLM
OT  - coronavirus disease 2019
OT  - immune response
OT  - interleukin-6
EDAT- 2021/02/24 06:00
MHDA- 2021/03/11 06:00
CRDT- 2021/02/23 17:33
PHST- 2021/02/23 17:33 [entrez]
PHST- 2021/02/24 06:00 [pubmed]
PHST- 2021/03/11 06:00 [medline]
AID - 10.1089/jir.2020.0135 [doi]
PST - ppublish
SO  - J Interferon Cytokine Res. 2021 Feb;41(2):37-43. doi: 10.1089/jir.2020.0135.